来凯医药与礼来签署LAE102临床合作协议

财中社11-20 13:27

　　财中社11月20日电来凯医药-B（02105）发布自愿公告，宣布与礼来公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，礼来将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。

　　LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。临床前模型显示，LAE102能够增加肌肉并减少脂肪，与GLP-1受体激动剂联用时可进一步降低脂肪并显著减少因GLP-1受体激动剂导致的肌肉流失，因此被视为高质量的体重控制候选药物。公司提醒股东及潜在投资者，LAE102的最终成功开发及商业化仍存在不确定性。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2484166153?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-20 13:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484166153","market":"hk","top_or_hot":-1,"title":"来凯医药与礼来签署LAE102临床合作协议","media":"财中社","content":"<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02105&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　<strong>财中社11月20日电</strong><span><a href=\"https://laohu8.com/S/02105\">来凯医药-B</a></span>（02105）发布自愿公告，宣布与<span><a href=\"https://laohu8.com/S/LLY\">礼来</a></span><span></span>公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，<span href=\"http://quote.eastmoney.com/unify/r/106.LLY\" target=\"_blank\" web=\"1\">礼来</span>将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。</p><p>　　LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。临床前模型显示，LAE102能够增加肌肉并减少脂肪，与GLP-1受体激动剂联用时可进一步降低脂肪并显著减少因GLP-1受体激动剂导致的肌肉流失，因此被视为高质量的体重控制候选药物。公司提醒股东及潜在投资者，LAE102的最终成功开发及商业化仍存在不确定性。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>来凯医药与礼来签署LAE102临床合作协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n来凯医药与礼来签署LAE102临床合作协议\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">财中社</strong><span class=\"h-time small\">2024-11-20 13:27</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p><img border=\"0\" height=\"276\" src=\"https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.02105&amp;imageType=k&amp;token=28dfeb41d35cc81d84b4664d7c23c49f&amp;at=1\" width=\"578\"/></p><p>　　<strong>财中社11月20日电</strong><span><a href=\"https://laohu8.com/S/02105\">来凯医药-B</a></span>（02105）发布自愿公告，宣布与<span><a href=\"https://laohu8.com/S/LLY\">礼来</a></span><span></span>公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，<span href=\"http://quote.eastmoney.com/unify/r/106.LLY\" target=\"_blank\" web=\"1\">礼来</span>将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。</p><p>　　LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。临床前模型显示，LAE102能够增加肌肉并减少脂肪，与GLP-1受体激动剂联用时可进一步降低脂肪并显著减少因GLP-1受体激动剂导致的肌肉流失，因此被视为高质量的体重控制候选药物。公司提醒股东及潜在投资者，LAE102的最终成功开发及商业化仍存在不确定性。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202411203245418615.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.SGD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","start_time":0,"source_url":"http://finance.eastmoney.com/a/202411203245418615.html","article_id":"2484166153","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484166153","pubTimestamp":1732080459,"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"财中社11月20日电来凯医药-B（02105）发布自愿公告，宣布与礼来公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，礼来将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0079474960.USD":"联博美国增长基金A","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","02105":"来凯医药-B","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LLY":"礼来","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SG9999015978.USD":"利安颠覆性创新基金A","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","BK4516":"特朗普概念","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Laikai Pharmaceuticals and Eli Lilly signed LAE102 clinical cooperation agreement","themeId":"07e0b9a8029060879506d5b591f8f763","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1,"LLY":1},"content_text":"财中社11月20日电来凯医药-B（02105）发布自愿公告，宣布与礼来公司签订了一项临床合作协议，旨在支持和加速LAE102针对肥胖症治疗的全球临床开发。根据协议，礼来将负责在美国执行一项I期研究并承担相关费用，而公司则保留LAE102的全球权利。　　LAE102是一种自主研发的单克隆抗体，针对在肌肉再生和脂肪代谢中发挥重要作用的ActRIIA受体。临床前模型显示，LAE102能够增加肌肉并减少脂肪，与GLP-1受体激动剂联用时可进一步降低脂肪并显著减少因GLP-1受体激动剂导致的肌肉流失，因此被视为高质量的体重控制候选药物。公司提醒股东及潜在投资者，LAE102的最终成功开发及商业化仍存在不确定性。（文章来源：财中社）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484166153"}